Tibetan medicine Herpetospermum caudigerum Wall. (HCW) has long been employed to treat hepatitis, inflammatory diseases and jaundice according to the records of "The Four Medical Tantras" in China. This study was investigated to explore the protective effects of HCW on hepatic fibrosis and the possible mechanism in a rat model. Hepatic fibrosis was established by intragastric administration of 3 ml/kg carbon tetrachloride (CCl 4 ) twice a week for 6 weeks. CCl 4 -treated rats were received HCW (1 and 3 g/kg/d) and silymarin (0.1 g/kg/d) from 3 to 6 weeks. The results showed that HCW could significantly decrease the levels of AST, ALT, HA, LN, PCIII, Col IV, TNF-a, IL-1b and IL-6. Moreover, HCW could effectively inhibit collagen deposition and reduce the pathological damage. Analysis experiments finally exhibited that HCW was able to markedly inhibit hepatic fibrosis by modulating the expressions of NF-jB p65, IjBa, Samd3 and TGF-b1 proteins. Therefore, our results suggest that HCW has hepatoprotective activity against CCl 4 -induced hepatic fibrosis in rats by regulating the inflammatory responses.
| INTRODUCTION
Hepatic fibrosis is a serious disease which affects human health around the world. 1 Evidences suggest that the pathogenesis of hepatic fibrosis is related to the inflammation in activated hepatic stellate cells. 2, 3 During the activation of hepatic stellate cells, plenty of pro-inflammatory cytokines including interleukin-6 (IL-6),
IL-1b and tumour necrosis factor a (TNF-a) are produced and play important pathogenic roles. 4 Transforming growth factor-b1 (TGFb1), nuclear factor-jB (NF-jB) and multiple growth factors can also promote the activation of hepatic stellate cells and accumulation of extra cellular matrix proteins which contributed to fibrosis. 5 To control the cirrhosis progression, hepatoprotective drugs are used properly at the stage of hepatic fibrosis. Recently, researchers identify the effective hepatoprotective drugs from herbal medicines due to their low toxicity and free from side effects.
Herpetospermum caudigerum Wall. (HCW), a well-known Tibetan medicine, is used to treat hepatitis, inflammatory diseases and jaundice according to the records of "The Four Medical Tantras" in China. It has the function of clearing heat and regulating "Ci ba dang jiu" in Tibetan medicine theory. Previous studies have showed that
HCW is effective on decreasing inflammatory responses and inhibiting lipid peroxidation in CCl 4 -treated mice. [6] [7] [8] On the basis of these researches, our present study is designed to further investigate the hepatoprotective activity of HCW and the effect on modulating All rats were randomly divided into 5 groups (n = 12 per group):
normal control rats and CCl 4 -treated model rats were orally received 3 ml/kg olive oil and 3 ml/kg CCl 4 (mixed 1:1 in olive oil; SigmaAldrich, Co., MO, USA) twice a week for 6 weeks and normal saline daily from week 3 to week 6, respectively; rats in treatment groups were orally received 3 ml/kg CCl 4 twice a week for 6 weeks and silymarin (0.1 g/kg) or HCW (1 and 3 g/kg) daily from week 3 to week 6.
At the end of 6 weeks, rats were killed after overnight fast.
Serum samples and liver samples were collected. Some liver tissues immediately were stored at À80°C for analysis, and the others were used for histopathologic examination. 
| Histopathological examination
Liver tissues were instantly fixed in 10% formalin and processed by routine histopathological procedures. The samples were stained with haematoxylin and eosin (HE) for photomicroscopic assessment.
| Immunohistochemical analysis
Liver tissues were fixed in 4% PFA and sectioned in 50 lm/piece.
The section was initially permeabilized with 0.4% Triton X-100 and 1% BSA for 2 hours and then incubated with anti-TGF-b1 and anti- P < .001 as compared with the normal control group; *P < .05, **P < .01, ***P < .001 as compared with the CCl 4 -treated model group. 
| Western blot analysis
Liver tissues were homogenized in RIPA buffer with 1% PMSF and phosphatase inhibitor. The equal amount of proteins was separated in 10% SDS-PAGE gel and then transferred onto PVDF membranes (Millipore, USA). After blocked in 5% BSA, the membranes were incubated with primary antibodies (1:1000; Cell Signaling Technology, Beverly, MA, USA) at 4°C overnight. The membranes were then washed and incubated with the secondary antibodies for 2 hours.
Finally, the membranes were exposed to X-ray film for 1 minute.
The relative expression of various proteins was quantified by densitometric scanning using image analysis system.
| Statistical analysis
All of the data were presented as mean AE SD. Divergence between groups was compared by one-way analysis of variance (ANOVA) with Tukey's multiple comparison test. P < .05 was considered as significant.
| RESULTS

| Identification of HCW
Four compounds (dehydrodiconiferyl alcohol, herpetrione, herpetin and herpetotriol) were identified by comparing the individual peak retention times with those of the authentic reference standards (Figure 1 ).
| Effect of HCW on biochemical parameters
As illustrated in Figure 2A and Table 1 , the serum levels of AST, ALT, HA, LN, PCIII and Col IV in CCl 4 -treated rats were significantly higher than those of the normal control rats, while treatment with HCW (1 and 3 g/kg) and silymarin (0.1 g/kg) effectively decreased these levels (P < .05).
In addition, there were significant increased levels of TNF-a, IL-6 and IL-1b in CCl 4 -treated rats both in serum and in liver tissues. To the respective, however, the production of TNF-a, IL-6 and IL-1b was effectively inhibited by HCW (1 and 3 g/kg) or silymarin (0.1 g/kg) ( Figure 2B and C) . 
| Immunohistochemical analysis
The expression of TGF-b1 and NF-jB p65 proteins in liver tissues was determined by immunohistochemical staining. The expression of TGFb1 and NF-jB p65 proteins was significantly up-regulated in CCl 4 -treated rats, while HCW (1 and 3 g/kg) or silymarin (0.1 g/kg) obviously ameliorated these situations (as shown in Figure 3B and C). 
| DISCUSSION
Hepatic fibrosis is associated with most chronic liver diseases which results in significant mortality rate around the world. Attentions have been focused on the inflammation-related pathways as promising therapies for hepatic fibrosis. In the present study, we demonstrated that HCW administration prevented the development of hepatic fibrosis in CCl 4 -treated rats.
CCl 4 is a hepatotoxin and has been widely adopted for experimental induction of hepatic fibrosis. 9 In hepatic fibrosis, the increased levels of AST, ALT, HA, LN, PCIII and Col IV indicate the ability of CCl 4 to solubilize the lipid components and alter the ion channels of bio-membranes. In our present study, the hepatic fibrosis However, which is the exert compound that contributes to the effect of HCW on hepatic fibrosis? As reported, dehydrodiconiferyl alcohol inhibits the activation of NF-jB protein in LPS-treated macrophage and suggests as an potential agent for the treatment of inflammatory diseases. 15, 16 Herpetrione and herpetin have hepatoprotective effect on CCl4-treated mice. 17, 18 Pinoresinol downregulated the inflammatory mediators by inhibiting the expression of NFjB and AP-1 proteins in CCl4-induced liver injury. 19 On the basis of these above-mentioned researches, we suggest that the comprehensive effect of these compounds on HCW contributes to the hepatoprotective effect of HCW. Whether other compounds have the hepatoprotective effect or not needs to be addressed in our future research.
In conclusion, the present study demonstrates that HCW has effectively therapeutic activity in the CCl 4 -induced hepatic fibrosis in rats. The preliminary exploration of the underlying mechanisms exerts the hepatic protection via the modulations of NF-jB and TGF-b1/Smad3 signalling pathways. However, further researches are needed for more details in future. Therefore, based on our present study, HCW may be considered as a promising drug for the prevention of hepatic fibrosis. 
ACKNOWLEDG EMENTS
CONFLI CT OF INTEREST
The authors confirm that there are no conflicts of interest.
O R C I D
Lvyi
Chen http://orcid.org/0000-0002-4318-3033
